Myeloid Malignancy Interest Group

Information about the newly created Myeloid Malignancy Interest Group will be posted soon. Please address any questions to Steven Pavletic, M.D. Also, please join us for the inaugural meeting on Monday, April 22, from 2:30 to 4:30 p.m. in the first-floor conference room of Building 50 on the NIH Bethesda campus.

Representatives of this interest group include:
Peter D. Aplan, M.D.
Christopher S. Hourigan, M.D., D.Phil.
Paul Liu, Ph.D.
Steven Z. Pavletic, M.D.
Nirali N. Shah, M.D.

Join us for our inaugural meeting and mini-symposium on Monday, April 22, from 2:30 to 4:30 p.m. in the Building 50 first-floor conference room.

AGENDA

2:30 — Welcome and introductions
Christopher Hourigan, NHLBI
Steven Pavletic, NCI
Peter Aplan, NCI
Paul Liu, NHGRI 
Nirali Shah, NCI
2:35 — NIH Deputy Director for Intramural Research 
Michael Gottesman, NIH, OD 
2:45 — NIH Myeloid malignancy research and SIG
Steven Pavletic, NCI, CCR
3:00 — Myelodysplastic syndromes – from lab to clinic
Dan Larson, NCI, CCR
3:20 — Clofarabine – bortezomib Ph1 update and rationale
Naoko Takebe, NCI, DCTD
3:35 — Clofarabine – bortezomib trial MDS case studies
Naoko Takebe, NCI, DCTD
Alina Dulau-Florea, NIH CC
Katherine Calvo, NIH, CC
Christopher Hourigan, NHLBI, HB
4:00 — Group photograph for “The Catalyst” 
4:15 — Cookies and tea or coffee refreshments
4.30 — Adjourn

Also please block your calendars for July 12, the NIH MDS Research Symposium for community oncologists — https://ncifrederick.cancer.gov/events/conferences/NCIMDS2019.